-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stomach cancer is the fifth most common cancer in the world and the third leading cause of death.
china, stomach cancer is the second largest tumor after lung cancer, and its morbidity and mortality rate account for 44% and 50% of the global incidence and death of stomach cancer, respectively.
broad definition of stomach cancer, including gastroesophageal joint (GEJ) cancer, which forms at the junction of the stomach and esophageal, can be attributed to stomach cancer.
compared with stomach cancer, the prevalence of gastroesophageal cancer is low, but it is on the rise.
because many patients with stomach cancer are unable to withstand follow-up treatment due to the deterioration of their condition, first-line treatment is often the best chance for patients with stomach or gastroesophageal cancer to achieve results.
esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of death.
Although the histological characteristics of esophageal cancer vary by region, squamous cell carcinoma and adenocarcinoma are still the two most common types, accounting for nearly 85% and 15% of the total number of esophageal cancer patients, respectively.
most people with esophageal cancer are diagnosed with advanced stages and their daily lives, including their diet, are affected.
will complete a comprehensive assessment of the available data from the CheckMate-649 study and work with researchers to present the results at a later academic conference.
, the study and its results will also be discussed with the health administration.
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach, gastroesophageal connecting or esophageal adenocarcinoma.
this part of the study is still in the process of data maturing, hundreds of meishi Guibao blind to this data.
: The first confirmed survival benefit from the first-line treatment of stomach and esophageal adenocarcinoma with Odivo combined chemotherapy. Retrieved August 11, 2020, from.
